{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T06:45:28Z","timestamp":1743749128277},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>Obesity, a chronic multifactorial disease, has been on the rise in the United States in recent years. It paves a way to other chronic conditions and related morbidity and mortality. The treatment of obesity should have a chronic approach involving lifestyle modifications from the very beginning. Along with reduced calorie diet, increased physical activity, and behavior modifications, various short- and long-term pharmacological agents are available to help with the weight loss. For qualifying patients, selection of an appropriate agent based on its mechanism, efficacy, and safety profile as well as patient preference can provide desired outcomes. This medical weight management should be a multidisciplinary approach involving nurses to provide continuous patient education and motivation.<\/jats:p>","DOI":"10.1097\/nor.0000000000000643","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T23:06:20Z","timestamp":1585263980000},"page":"121-127","source":"Crossref","is-referenced-by-count":3,"title":["Obesity Treatment"],"prefix":"10.1097","volume":"39","author":[{"given":"Khyati","family":"Patel","sequence":"first","affiliation":[{"name":"Khyati Patel, PharmD, BCACP,Assistant Professor, Department of Pharmacy Practice, Rosalind Franklin University of Medicine and Science, North Chicago, IL."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"2","key":"R1-20230822","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: A randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity"},{"key":"R2-20230822","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1002\/oby.20660","article-title":"Expert panel report: Guidelines (2013) for the management of overweight and obesity in adults","volume":"22","year":"2014","journal-title":"Obesity"},{"issue":"2","key":"R3-20230822","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: An Endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"5","key":"R4-20230822","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity"},{"key":"R5-20230822","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/BLO.0b013e3181576035","article-title":"Role of obesity on the risk for total hip or knee arthroplasty","volume":"465","author":"Bourne","year":"2007","journal-title":"Clinical Orthopaedics and Related Research"},{"issue":"1","key":"R6-20230822","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12328","article-title":"Update on obesity pharmacotherapy","volume":"1311","author":"Bray","year":"2014","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"7","key":"R9-20230822","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with Type 2 diabetes: The SCALE diabetes trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"10","key":"R10-20230822","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial","volume":"96","author":"Fidler","year":"2011","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"5","key":"R11-20230822","doi-asserted-by":"crossref","first-page":"w822","DOI":"10.1377\/hlthaff.28.5.w822","article-title":"Annual medical spending attributable to obesity: Payer-and service-specific estimates","volume":"28","author":"Finkelstein","year":"2009","journal-title":"Health Affairs"},{"issue":"9774","key":"R13-20230822","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"issue":"9741","key":"R14-20230822","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"R16-20230822","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with Type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"issue":"25","key":"R17-20230822","first-page":"S102","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"R18-20230822","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1517\/14740330903321485","article-title":"Orlistat: Current status in clinical therapeutics","volume":"8","author":"McClendon","year":"2009","journal-title":"Expert Opinion on Drug Safety"},{"issue":"11","key":"R19-20230822","doi-asserted-by":"crossref","first-page":"683","DOI":"10.5435\/JAAOS-22-11-683","article-title":"Obesity, orthopaedics, and outcomes","volume":"22","author":"Mihalko","year":"2014","journal-title":"Journal of American Academy of Orthopaedic Surgeons"},{"issue":"7","key":"R21-20230822","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","article-title":"Randomized placebo controlled clinical trial of lorcaserin for weight loss in Type 2 diabetes mellitus: The BLOOM-DM study","volume":"20","author":"O'Neil","year":"2012","journal-title":"Obesity"},{"issue":"1","key":"R22-20230822","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"R23-20230822","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"R24-20230822","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of Type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"issue":"1","key":"R26-20230822","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: The COR\u2013BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity"},{"issue":"1","key":"R27-20230822","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.2013.281361","article-title":"Long-term drug treatment for obesity: A systematic and clinical review","volume":"311","author":"Yanovski","year":"2014","journal-title":"JAMA"},{"issue":"12","key":"R28-20230822","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jama.2015.1617","article-title":"Naltrexone extended-release plus bupropion extended-release for treatment of obesity","volume":"313","author":"Yanovski","year":"2015","journal-title":"JAMA"},{"key":"R29-20230822","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1479-5868-10-131","article-title":"Nurses' self-efficacy and practices relating to weight management of adult patients: A path analysis","volume":"10","author":"Zhu","year":"2013","journal-title":"The International Journal of Behavioral Nutrition and Physical Activity"}],"container-title":["Orthopaedic Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/NOR.0000000000000643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:37:42Z","timestamp":1692751062000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/NOR.0000000000000643"}},"subtitle":["A Focus on Pharmacotherapy of Weight Management"],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/nor.0000000000000643","relation":{},"ISSN":["0744-6020"],"issn-type":[{"value":"0744-6020","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}